CeriBell (NASDAQ:CBLL – Get Free Report) shares fell 9.2% on Friday . The company traded as low as $20.75 and last traded at $20.91. 77,666 shares changed hands during trading, a decline of 57% from the average session volume of 179,863 shares. The stock had previously closed at $23.02.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on CBLL shares. JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price on the stock. Canaccord Genuity Group increased their price objective on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 9th. TD Cowen boosted their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. William Blair assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell presently has a consensus rating of “Buy” and a consensus price target of $32.60.
View Our Latest Analysis on CeriBell
CeriBell Trading Down 10.9 %
CeriBell (NASDAQ:CBLL – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million. Research analysts predict that CeriBell will post -2.46 EPS for the current year.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
- Five stocks we like better than CeriBell
- ETF Screener: Uses and Step-by-Step Guide
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- The Basics of Support and Resistance
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What Is WallStreetBets and What Stocks Are They Targeting?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
